Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Maryland State Retirement & Pension System

Maryland State Retirement & Pension System decreased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 15.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,688 shares of the medical equipment provider’s stock after selling 1,969 shares during the quarter. Maryland State Retirement & Pension System’s holdings in Hologic were worth $660,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of HOLX. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of Hologic in the first quarter valued at approximately $42,000. Raiffeisen Bank International AG acquired a new stake in shares of Hologic in the fourth quarter valued at approximately $49,000. Allworth Financial LP increased its stake in shares of Hologic by 46.0% in the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock valued at $40,000 after purchasing an additional 216 shares during the period. Larson Financial Group LLC increased its stake in shares of Hologic by 6,016.7% in the first quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 722 shares during the period. Finally, West Financial Advisors LLC acquired a new stake in shares of Hologic in the first quarter valued at approximately $50,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Trading Up 1.5%

Shares of NASDAQ:HOLX opened at $68.98 on Thursday. The stock has a market capitalization of $15.34 billion, a price-to-earnings ratio of 28.62, a PEG ratio of 2.47 and a beta of 0.49. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.39. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. The company has a 50 day moving average price of $65.43 and a 200 day moving average price of $62.69.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.03. The firm had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The firm’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period last year, the firm posted $1.06 earnings per share. On average, research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have commented on HOLX shares. Morgan Stanley raised their price target on shares of Hologic from $65.00 to $69.00 and gave the company an “equal weight” rating in a research note on Thursday, July 31st. Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and raised their price target for the company from $60.00 to $80.00 in a research note on Wednesday, July 9th. Wall Street Zen lowered shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, May 5th. Evercore ISI raised their price objective on shares of Hologic from $62.00 to $68.00 and gave the company an “in-line” rating in a research note on Tuesday, July 8th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Hologic in a research note on Tuesday, May 27th. Ten research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $77.83.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.